Choose Your Location
|
![]() |
ST. LOUIS (Map) -
"The expansion of the Human Protein Atlas dramatically advances
Sigma-Aldrich's antibody offerings," said Dr.
Prestige Antibodies are highly validated for specificity and are designed to have low cross-reactivity to other human proteins. Each Prestige antibody is accompanied by 576 tissue immunohistochemistry (IHC) images and 118 cell and cell line immunocytochemistry (ICC) images. These images, as well as immunofluorescence (IF) and western blotting (WB) data, are publicly accessible via the Human Protein Atlas (http://www.proteinatlas.org). Prestige Antibodies are optimized on a single protocol and are tailored for high throughput operations, providing the potential for significant time and cost savings for researchers.
Sigma-
Prestige Antibodies(TM) are available at http://www.sigma.com/prestige, where customers can search or browse for available antibodies by specific gene name and ID, or by keywords.
About Sigma-Aldrich: Sigma-Aldrich is a leading Life Science and High
Technology company. Its biochemical and organic chemical products and kits
are used in scientific and genomic research, biotechnology, pharmaceutical
development, the diagnosis of disease and as key components in
pharmaceutical and other high technology manufacturing. The Company has
customers in life science companies, university and government
institutions, hospitals, and in industry. Over one million scientists and
technologists use its products. Sigma-
About Atlas Antibodies: Atlas Antibodies was founded in 2006 by
researchers at the Royal Institute of Technology (KTH) in
Cautionary Statement: This release contains forward-looking statements relating to future performance, goals, strategic actions and initiatives and similar intentions and beliefs and other statements regarding the Companies' expectations, goals, beliefs, intentions and the like, which involve assumptions regarding the Companies' operations and conditions in the markets the Companies serve. The Companies do not undertake any obligation to update these forward-looking statements.
|
|


